Cost-Effectiveness of Real-World Administration of Concomitant Viscum album L. Therapy for the Treatment of Stage IV Pancreatic Cancer
Table 3
Age-adjusted costs and cost-effectiveness measures from hospital’s perspective.
C
Costs
Hospital costs, mean €, (95%CI)
10068.97 (6659.87; 13478.06)
12267.94 (9593.67; 14942.20)
2198.97
Outcomes
OS, median months, (95% CI)
5.63 (3.37; 8.63)
8.43 (6.50; 12.47)
2.8
OS, mean months, (95% CI)
7.1 (4.75; 9.45)
10.6 (8.44; 22.86)
3.5
Hospital stays, mean number, (95% CI)
2.21 (−0.59; 5.01)
3.37 (−1.78; 8.53)
1.16
Hospitalization length, mean days, (95% CI)
12.47 (−0.59–5.01)
13.90 (−1.42; 29.23)
1.43
CE outcomes
Costs per month OS, mean €/mean months
1418.16
1157.35
−260.81
Costs per hospital stay, mean €/mean number
4556.10
3640.33
−915.77
Costs per days of hospitalization, mean €/mean days
807.50
882.59
75.09
Hospital’s costs per mPC patient according to the treatment group; adjusted for age; €, euro; CI, confidence interval; OS, overall survival; CE, cost-effectiveness; C, C group; , group; Δ, difference.
